Compound Therapeutics Inc.
This article was originally published in Start Up
Compound Therapeutics has engineered proteins, called Adzymes, which bind to targets with the specificity of antibodies but unlike them destroy their targets using an attached enzyme.
You may also be interested in...
Ambrx is using its technology for engineering proteins with novel amino acids--beyond the 20 that oocur in nature--to enhance the properties of proteins whose potential therapeutic uses, as well as liabilities, are known.
While companies are working hard to create new manufacturing capacity for biologics, protein production, which requires more highly trained and experienced workers, will remain constrained by a lack of qualified staff. Companies will need to act on a variety of fronts to deal with the problem--among them, more co-op hiring, and more partnering with companies with the requisite manufacturing capacity.
Boston-area start-up engeneOS Inc. aspires to build molecular machines with starting materials that come from nature. The firm aims to take advantage of the the fact that proteins and nucleic acids have evolved highly specific capabilities over thousands of years. Management sees them as components that can be catalogued, combined and harnessed to carry out new tasks.